2-(1-Benzyl-indolyl-3)-propionsaeure | 94004-57-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 2-(1-Benzyl-indolyl-3)-propionsaeure
• 英文别名: 2-(1-benzyl-indol-3-yl)-propionic acid；2-(1-Benzylindol-3-yl)propanoic acid
• CAS: 94004-57-6
• 化学式: C₁₈H₁₇NO₂
• 分子量: 279.338
• InChiKey: GAHBTSIQOMDKGQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  42.2
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• Substituted hydrazones as inhibitors of cyclooxygenase-2
  申请人：——

  公开号：US20030187035A1

  公开（公告）日：2003-10-02

  Compounds useful as inhibitors of cyclooxygenase-2 activity have the formulae I or Ia: 1 wherein: Q 1 , Q 2 , n, m, X, Y and R are as defined herein.

  具有下列式子I或Ia的化合物可用作环氧合酶-2活性抑制剂：1其中：Q1、Q2、n、m、X、Y和R的定义如下。
• Pyrazoline derivatives useful for the treatment of cancer
  申请人：Cuberes Altisen Rosa

  公开号：US20070066651A1

  公开（公告）日：2007-03-22

  Compounds of formula (I) wherein: X is selected from the group consisting of trihalomethyl, C 1 -C 6 alkyl, and a group of formula (II) wherein: R 3 and R 4 are independently selected from the group consisting of hydrogen; halogen; hydroxyl; nitro; C 1 -C 6 alkyl; C 1 -C 6 alkoxy; carboxy; C 1 -C 6 trihaloalkyl; and cyano; Z is selected from the group consisting of substituted and unsubstituted aryl; or a pharmaceutically acceptable salt thereof. The compounds are inhibitors of cyclooxygenase-2 activity. They are useful for treating cyclooxygenase-mediated disorders, including, for example, inflamation, neoplastic disorders and angiogenesis-mediated disorders.

  化合物的公式（I），其中： X被选自三卤甲基，C1-C6烷基和公式（II）中的一组，其中： R3和R4分别被选自氢，卤素，羟基，硝基，C1-C6烷基，C1-C6烷氧基，羧基，C1-C6三卤代烷基和氰基的一组； Z被选自取代和未取代芳基；或其药学上可接受的盐。这些化合物是环氧合酶-2活性的抑制剂。它们可用于治疗环氧合酶介导的疾病，包括例如炎症，肿瘤性疾病和血管生成介导的疾病。
• 1-Indolylalkyl-4-(alkoxy-pyrimidinyl)piperazines
  申请人：Bristol-Myers Squibb Company

  公开号：EP0464604A2

  公开（公告）日：1992-01-08

  Certain 1-indolylalkyl-4-(alkoxypyrimidinyl) piperazines are useful antidepressant compounds.

  某些 1-吲哚烷基-4-(烷氧基嘧啶基)哌嗪是有用的抗抑郁化合物。
• Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases
  申请人：The Brigham and Women's Hospital, Inc.

  公开号：EP1520590A1

  公开（公告）日：2005-04-06

  The invention involves methods for characterising an individual's risk profile of developing a future cardiovascular disorder by obtaining a level of the marker of systemic inflammation in the individual. The invention also involves methods for evaluating the likelihood that an individual will benefit from treatment with an agent for reducing the risk of future cardiovascular disorder.

  本发明涉及通过获取个人体内的全身炎症标志物水平来描述其未来罹患心血管疾病的风险特征的方法。本发明还涉及评估个体从使用降低未来心血管疾病风险的药物治疗中获益的可能性的方法。
• Soluble CD40L (CD154) as a prognostic marker of atherosclerotic diseases
  申请人：The Brigham and Women's Hospital, Inc.

  公开号：US20030152566A1

  公开（公告）日：2003-08-14

  This invention involves the new use of a diagnostic test to determine the risk of atherosclerotic diseases such as myocardial infarction and stroke, particularly among individuals with no signs or symptoms of current disease and among nonsmokers. Further, this invention involves the new use of a diagnostic test to assist physicians in determining which individuals at risk will preferentially benefit from certain treatments designed either to prevent first or recurrent myocardial infarctions and strokes, or to treat acute and chronic cardiovascular disorders. Methods for treatment also are described.

  本发明涉及一种诊断测试的新用途，以确定动脉粥样硬化性疾病如心肌梗塞和中风的风险，特别是在目前没有疾病迹象或症状的人和不吸烟者中。此外，本发明还涉及诊断检测的新用途，以协助医生确定哪些高危人群将优先受益于某些治疗方法，这些治疗方法旨在预防首次或复发性心肌梗塞和中风，或治疗急性和慢性心血管疾病。此外，还介绍了治疗方法。